NAS:ASND (Denmark) Also trade in: Germany

Ascendis Pharma A/S

$ 116.83 -2.06 (-1.73%)
Volume: 170,184 Avg Vol (1m): 325,552
Market Cap $: 5.48 Bil Enterprise Value $: 4.70 Bil
P/E (TTM): 0.00 P/B: 6.40
Earnings Power Value -706.89
Net Current Asset Value 17.47
Tangible Book 18.58
Projected FCF 0
Median P/S Value 79.77
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 8/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt range over the past 10 years
Min: 68.56, Med: 10000, Max: 10000
Current: 10000
68.56
10000
Equity-to-Asset 0.94
Equity-to-Asset range over the past 10 years
Min: 0.16, Med: 0.9, Max: 0.95
Current: 0.94
0.16
0.95
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 63.24
DISTRESS
GREY
SAFE
Beneish M-Score 8.49
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 6.86%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -1115.33
Operating Margin range over the past 10 years
Min: -7290.26, Med: -515.21, Max: 25.87
Current: -1115.33
-7290.26
25.87
Net Margin % -900.61
Net Margin range over the past 10 years
Min: -8097.84, Med: -405.54, Max: 19.99
Current: -900.61
-8097.84
19.99
ROE % -35.49
ROE range over the past 10 years
Min: -71.9, Med: -38.24, Max: 139.69
Current: -35.49
-71.9
139.69
ROA % -32.70
ROA range over the past 10 years
Min: -65.14, Med: -33.22, Max: 15.98
Current: -32.7
-65.14
15.98
ROC (Joel Greenblatt) % -1932.67
ROC (Joel Greenblatt) range over the past 10 years
Min: -5343.32, Med: -1499.83, Max: 303.45
Current: -1932.67
-5343.32
303.45
3-Year Total Revenue Growth Rate 10.80
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -58.6, Max: -7.6
Current: -7.6
0
-7.6
3-Year Total EBITDA Growth Rate -60.00
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -33.3
Current: -33.3
0
-33.3
3-Year EPS w/o NRI Growth Rate -33.50
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -33.5
Current: -33.5
0
-33.5

» ASND's 30-Y Financials

Financials (Next Earnings Date: 2019-08-29)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ASND

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325411    SIC : 2833
Compare NAS:HALO NAS:CBPO NAS:PBYI SZSE:300009 NAS:ANAB NAS:FOLD NYSE:EBS SHSE:600161 XBRU:ARGX NAS:ACAD SZSE:002821 XSWX:GALE XSWX:IDIA NAS:CRSP NAS:RARE NAS:IMMU SZSE:002603 NAS:CLVS SZSE:000990 HKSE:00570
Traded in other countries A71.Germany
Address Tuborg Boulevard 5, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP etc. It operates mainly in USA, Germany, and Switzerland and derives the majority of its revenue from the US.

Ratios

Current vs industry vs history
PB Ratio 6.40
PB Ratio range over the past 10 years
Min: 2.43, Med: 5.53, Max: 10.24
Current: 6.4
2.43
10.24
PS Ratio 273.63
PS Ratio range over the past 10 years
Min: 15.85, Med: 186.82, Max: 5905
Current: 273.63
15.85
5905
EV-to-EBIT -28.90
EV-to-EBIT range over the past 10 years
Min: -29.86, Med: -9.85, Max: -3.6
Current: -28.9
-29.86
-3.6
EV-to-EBITDA -29.27
EV-to-EBITDA range over the past 10 years
Min: -31.2, Med: -10, Max: -3.6
Current: -29.27
-31.2
-3.6
EV-to-Revenue 260.13
EV-to-Revenue range over the past 10 years
Min: 15.4, Med: 182.1, Max: 6352.5
Current: 260.13
15.4
6352.5
Current Ratio 22.32
Current Ratio range over the past 10 years
Min: 0.77, Med: 9.87, Max: 22.32
Current: 22.32
0.77
22.32
Quick Ratio 22.32
Quick Ratio range over the past 10 years
Min: 0.77, Med: 9.87, Max: 22.32
Current: 22.32
0.77
22.32
Days Sales Outstanding 0.09
Days Sales Outstanding range over the past 10 years
Min: 0.09, Med: 33.73, Max: 133.93
Current: 0.09
0.09
133.93

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -17.80
3-Year Share Buyback Rate range over the past 10 years
Min: -44.2, Med: -29.7, Max: 0
Current: -17.8
-44.2
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 6.29
Price-to-Tangible-Book range over the past 10 years
Min: 2.62, Med: 5.62, Max: 8.49
Current: 6.29
2.62
8.49
Price-to-Median-PS-Value 1.46
Price-to-Median-PS-Value range over the past 10 years
Min: 0.09, Med: 0.99, Max: 31.63
Current: 1.46
0.09
31.63
Earnings Yield (Joel Greenblatt) % -3.44
Earnings Yield (Greenblatt) range over the past 10 years
Min: -27.8, Med: -10.15, Max: -3.32
Current: -3.44
-27.8
-3.32

More Statistics

Revenue (TTM) (Mil) $ 18.12
EPS (TTM) $ -3.85
Beta 0.79
Volatility % 65.98
52-Week Range $ 53.21 - 133.96
Shares Outstanding (Mil) 46.93

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y